Design, synthesis and biological evaluation of second-generation benzoylpiperidine derivatives as reversible monoacylglycerol lipase (MAGL) inhibitors.
Animals
Antineoplastic Agents
/ chemical synthesis
Cell Line, Tumor
Cell Proliferation
/ drug effects
Drug Design
Enzyme Inhibitors
/ chemical synthesis
Humans
Mice
Molecular Dynamics Simulation
Monoacylglycerol Lipases
/ antagonists & inhibitors
Neoplasms
/ drug therapy
Piperidines
/ chemical synthesis
Benzoylpiperidine derivatives
MAGL
Monoacylglycerol lipase inhibitors
Journal
European journal of medicinal chemistry
ISSN: 1768-3254
Titre abrégé: Eur J Med Chem
Pays: France
ID NLM: 0420510
Informations de publication
Date de publication:
01 Jan 2021
01 Jan 2021
Historique:
received:
31
08
2020
revised:
16
09
2020
accepted:
17
09
2020
pubmed:
13
10
2020
medline:
21
4
2021
entrez:
12
10
2020
Statut:
ppublish
Résumé
An interesting enzyme of the endocannabinoid system is monoacylglycerol lipase (MAGL). This enzyme, which metabolizes the endocannabinoid 2-arachidonoylglycerol (2-AG), has attracted great interest due to its involvement in several physiological and pathological processes, such as cancer progression. Experimental evidences highlighted some drawbacks associated with the use of irreversible MAGL inhibitors in vivo, therefore the research field concerning reversible inhibitors is rapidly growing. In the present manuscript, the class of benzoylpiperidine-based MAGL inhibitors was further expanded and optimized. Enzymatic assays identified some compounds in the low nanomolar range and steered molecular dynamics simulations predicted the dissociation itinerary of one of the best compounds from the enzyme, confirming the observed structure-activity relationship. Biological evaluation, including assays in intact U937 cells and competitive activity-based protein profiling experiments in mouse brain membranes, confirmed the selectivity of the selected compounds for MAGL versus other components of the endocannabinoid system. An antiproliferative ability in a panel of cancer cell lines highlighted their potential as potential anticancer agents. Future studies on the potential use of these compounds in the clinical setting are also supported by the inhibition of cell growth observed both in cancer organoids derived from high grade serous ovarian cancer patients and in pancreatic ductal adenocarcinoma primary cells, which showed genetic and histological features very similar to the primary tumors.
Identifiants
pubmed: 33045662
pii: S0223-5234(20)30829-1
doi: 10.1016/j.ejmech.2020.112857
pii:
doi:
Substances chimiques
Antineoplastic Agents
0
Enzyme Inhibitors
0
Piperidines
0
Monoacylglycerol Lipases
EC 3.1.1.23
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
112857Informations de copyright
Copyright © 2020 Elsevier Masson SAS. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.